

**5. BIBLIOGRAPHY**

1. Abdel Tawab M, Kaunzinger A, Bahr U, Karas M, Wurglics M, and Schubert-Zsilavecz M .(2001), Development of a high-performance liquid chromatographic method for the determination of 11-keto- $\alpha$ -boswellic acid in human plasma, *Journal of Chromatography and Biomedical Application*, 761, 221– 227.
2. Achliya GS, Wadodkar SG, Dorle AK. (2004), Evaluation of sedative and anticonvulsant activities of Unmadnashak Ghrita, *Journal of Ethnopharmacology*, 94, 77–83.
3. Ahmed Al-Harrasi and Salim Al-Saidi. (2008), Phytochemical Analysis of the Essential Oil from Botanically Certified Oleogum Resin of *Boswellia sacra* (Omani Luban), *Molecules*, 13, 2181-2189
4. Altmann A et al. Boswellic acids activate p42MAPK and p38 MAPK and stimulate Ca<sup>2+</sup> mobilization. *Biochemical and Biophysical Research Communications*, 2002, 290:185–190.
5. Ambawade SD, Kasture VS, Kasture SB. (2002), Anticonvulsant activity of root and rhizome of *Glycyrrhiza glabra*, *Indian Journal of Pharmacology*, 34, 251-255.
6. Ammon HP, Mack T, Singh GB, Safayhi H. (1991), Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of *Boswellia serrata*, *Planta Medica*, 57, 203-207.
7. Ammon HP. (1996), Salai guggal – *Boswellia serrata*: from a herbal medicine to a specific inhibitor of leukotriene biosynthesis, *Phytomedicine*, 3, 67-70.
8. Ammon HP. (2002), Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases, *Wiener Medizinische Wochenschrift*, 152, 373-378.
9. Ana Flavia Schurmann da Silva, Jean Paulo de Andrade, Lia R.M. Bevilaqua Marcia Maria de Souza d, Ivan Izquierdo c, Amelia Teresinha Henriques a, Jose Angelo Silveira Zuanazzi. (2006), Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from *Hippeastrum vittatum*, *Pharmacology, Biochemistry and Behavior*, 85, 148–154.

10. Anonymous. (1998), The Ayurvedic Formulary of India, Govt. of India, New Delhi, Part-I, 3, 319-337.
11. Anonymous. (2005), *Boswellia serrata* Roxb. ex Colebr.(Sallaki), In: Quality Standard of Indian Medicinal Plants, Indian Council of Medicinal Research, New Delhi, India, 2, 19-24.
12. Astrid Kaunzinger, Alwin Baumeister, Klaus Cuda, Norbert Haring, Barbara Schug, Henning H. Blume, Klaus Raddatz, Gerhard Fischer, Manfred Schubert-Zsilavecz. (2002), *Journal of Pharmaceutical and Biomedical Analysis*, 28, 729–739.
13. Atal CK, Gupta OP, Singh GB. Salai guggal: A promising anti-arthritic and anti-hyperlipidemic agent. *British Journal of Pharmacology*, 1981, 74:203–204.
14. Barar FSK. (2004), *Essentials of Pharmacotherapeutics*, S.Chand and Company Ltd. Publishers, New Delhi.
15. Bastidas Ramirez BE, Navarro Ruiz N, Quezada Arellano JD, Ruiz Madrigal B, Villanueva Michel MT, Garzon P. (1998), Anticonvulsant effects of *Magnolia grandiflora* L. in the rat. *Journal of Ethnopharmacology*, 61, 143–152.
16. Bedevian AK. *Illustrated polyglottic dictionary of plant names*. Cairo, Medbouly Library, 1994.
17. Bhushan S, Kumar A, Malik F. (2007), A triterpenediol from *Boswellia serrata* induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells, *Apoptosis*, 12, 1911-1926.
18. Bienvenu E, Amabeoku GJ, Eagles PK, Scott G, Springfield EP. (2002), Anticonvulsant activity of aqueous extract of *Leonotis leonurus*, *Phytomedicine*, 9, 217 – 223.
19. Blanco MM, Costa CARA, Freire AO, Santos Jr, JG, Costa M. (2009), Neurobehavioral effect of essential oil of *Cymbopogon citratus* in mice, *Phytomedicine*, 16, 265-270.
20. Boden SE et al. Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid. *Molecular Pharmacology*, 2001, 60:267–273.

21. Borris, J. (1996). Natural products research perspectives from a major pharmaceutical company, Merck Research Laboratories, *Journal of Ethnopharmacology*, 51, 29.
22. Bowie D. (2008), Ionotropic glutamate receptors and CNS disorders, *CNS and Neurological Disorders-Drug Targets*, 7, 129-143.
23. Briggs GG, Freeman RK, Yaffe SJ. *Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk*. 4th ed. Baltimore: Williams and Wilkins; 1994.
24. Browning R. (1992), The electroshock model, neuronal network and antiepileptic drugs. in: Faingold, C.L., Fromm, G.H. (Eds.), *Drugs for Control of Epilepsy: Actions on Neuronal Networks in Seizure Disorders*. CRC Press, Boca Raton, FL, USA, p. 195-211.
25. Bruce, A.J., Baudry, M. (1995), Oxygen free radicals in rat limbic structures after kainate-induced seizures, *Free Radical Biology and Medicine*, 18, 993 - 1002.
26. Bruno B, Alessandro P, Andrea V, Anna MB. (2008), Comparison of the irritation potentials of *Boswellia serrata* gum resin and of acetyl-11-keto- $\beta$ -boswellic acid by in vitro cytotoxicity tests on human skin-derived cell lines, *Toxicology Letters*, 177, 144–149.
27. Buchele B and Simmet T. (2003), Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection, *Journal of Chromatography Analytical Technologies in the Biomedical and Life Sciences*, 795, 355–362.
28. Carlini EA. (2003), Plants and the central nervous system, *Pharmacol. Biochem. Behav*, 3, 501-512.
29. Chimakurthy J, Talasila EGK Murthy, Lokesh U. (2008), Protective role of curcumin in maximal electroshock induced seizures, memory impairment and neurotransmitters in rat brain, *Journal of Pre-Clinical and Clinical Research*, 2, No 1, 035-039.
30. Chopra RN, ed. *Indigenous drugs of India. Their medical and economic aspects*. Calcutta, India, Art Press, 1933.
31. Cockerell OC. (1996), The prognosis of epilepsy. In: Shorvon, S., Dreifuss, F., Fish, D., Thomas, D. (Eds.), *The treatment of epilepsy*. Blackwell Science, Oxford, pp. 97e113.

32. Culioli G, Mathe C, Archier P, Vieillescazes C. (2003), A lupane triterpene from frankincense (*Boswellia* sp., Burseraceae), *Phytochemistry*, 62, 537–541.
33. Cutting S, Lauchheimer A, Barr W, Devinsky O. Adult-onset idiopathic generalized epilepsy: clinical and behavioral features. *Epilepsia* 2001; 42:1395-8.
34. Database on medicinal plants used in Ayurveda. New Delhi. (2000), Central Council for Research in Ayurveda and Siddha, Department of ISM and H, Ministry of Health and Family Welfare, Government of India.
35. Deckers CLP, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos P, Renier WO, van Rijn CM. (2000), Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. *Epilepsia*, 41, 1364 – 1374.
36. Delgado JN, Remers WA (Eds.) (1998), Wilson and Gisvold's Textbook of Organic and Medicinal Pharmaceutical Chemistry, Lippincott-Raven, U.S.A.
37. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. *Neurology*. (1984),S 34:285-94.
38. Dhar ML et al. Screening of Indian plants for biological activity: part I. *Indian Journal of Experimental Biology*, 1968, 6:232–247.
39. Doose H, Neubauer BA. Preponderance of female sex in the transmission of seizure liability in idiopathic generalized epilepsy. *Epilepsy Res* 2001;43:103-14.
40. Doppelbauer A, Zeitlhofer J, Zifko U, Baumgartner C, Mayr N, Deecke L. Occurrence of epileptiform activity in the routine EEG of epileptic patients. *Acta Neurol Scand* 1993; 87:345-52.
41. Durner M, Keddache MA, Tomasini L, Shinnar S, Resor SR, Cohen J, et al. Genome scan of idiopathic generalised epilepsy: evidence for major susceptibility gene and modifying genes influencing the seizure type. *Ann Neurol*, (2001); 49:328-35.
42. Duwiejua M et al. Anti-inflammatory activity of resins from some species of the plant family Burseraceae. *Planta Medica*, 1993, 59:12–16.
43. Eadie MJ. Plasma antiepileptic drug monitoring in a neurological practice: a 25-year experience. *Ther Drug Monit* 1994; 16:458-68.

44. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. *Epilepsia* 2001; 42:796-803.
45. Epilepsy and pregnancy. *Drug Ther Bull* 1994; 32:49-51.
46. Erakovic, V., Zupan, G., Varljen, J., Laginja, J., Simonic, A. (2001), Altered activities of rat brain metabolic enzymes caused by pentylenetetrazol kindling and pentylenetetrazol-induced seizures, *Epilepsy Research*, 43, 165 - 173.
47. Etzel R. Special extract of *Boswellia serrata* (H15)\* in the treatment of rheumatoid arthritis. *Phytomedicine*, 1996, 3:91–94.
48. European Pharmacopoeia, 5th ed. Strasbourg, Directorate for the Quality Medicines of the Council of Europe (EDQM), 2005.
49. Fan AY, Lao L, Zhang RX, Zhou AN, Wang LB, Moudgil KD, Lee DYW, Ma ZZ, Zhang WY, Berman BM. (2005), Effects of an acetone extract of *Boswellia carterii* Birdw. (Burseraceae) gum resin on adjuvant-induced arthritis in lewis rats, *Journal of Ethnopharmacology*, 101, 104–109.
50. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at Chicago, IL (an online database available directly through the University of Illinois at Chicago or through the Scientific and Technical Network [STN] of Chemical Abstracts Services), 30 June 2005.
51. Fatehi M, Saleh TM, Hassanabad ZF, Farrokhfal K, Jafarzadeh M, Davodi S. (2005), A pharmacological study on *Berberis vulgaris* fruit extract, *Journal of Ethnopharmacology*, 102, 46–52.
52. Fusun Erdogan, Asuman Golgeli, Fehim Arman, and Ali Ozdemir Ersoy. (2004), The effects of pentylenetetrazole-induced status epilepticus on behavior, emotional memory, and learning in rats, *Epilepsy & Behavior*, 5, 388–393.
53. Ganzera M, Khan IA. A reversed phase high performance liquid chromatography method for the analysis of boswellic acids in *Boswellia serrata*. *Planta Medica*, 2001, 67:778–780.
54. Gerhard Luef, Markus Rauchenzauner. (2009), Epilepsy and hormones: A critical review, *Epilepsy & Behavior*, 15, 73 – 77.

- 
55. Gerhardt H et al. [Therapy of active Crohn disease with *Boswellia serrata* Extract H 15]. *Zeitschrift für Gastroenterologie*, 2001, 39:11–17 [in German]. 59 Gummi Boswellii.
56. Gerhardt H, Seifert F, Bhuvary P, Vogelsang H, Reppes R. (2001), Therapy of active Crohn disease with *Boswellia serrata* extract H15, *Z. Gastroenterol.*, 39, 11-17.
57. Gilani AH, Aziz N, Khan MA, Shaheen F, Jabeen Q, Siddiqui BS, Herzig JW. (2000), Ethnopharmacological evaluation of the anticonvulsant, sedative and antispasmodic activities of *Lavandula stoechas* L, *Journal of Ethnopharmacology*, 71, 161–167.
58. Girgune JB, Garg BD. Chemical investigation of the essential oil from *Boswellia serrata* Roxb. *Journal of Scientific Research*, 1979, 1:119–122.
59. Goyal RK et al. (2010). *Essential of clinical pharmacy*, B.S.Shah Prakashan
60. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World Health Organization, 1997 (WHO/FSF/FOS/97.7).
61. Gupta AK, Chitme HR. (2000), *Herbal Medicine for Health*, Eastern Pharmacist, 41, 41-44.
62. Gupta I et al. Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *European Journal of Medical Research*, 1998, 3:511–514.
63. Gupta I et al. Effects of gum resin of *Boswellia serrata* in patients with chronic colitis. *Planta Medica*, 2001, 67:391–395.
64. Gupta I, Gupta V, Parihar A, et al. (1998), Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study, *European Journal of Medical Research*, 3, 511-514.
65. Gupta I, Parihar A, Malhotra P, Gupta S. (2001), Effects of gum resin of *Boswellia serrata* in patients with chronic colitis, *Planta Medicaica*, 67, 391-395.
66. Gupta I, Parihar A, Malhotra P. (1997), Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis, *European Journal of Medical Research*, 2, 37-43.
67. Gupta, I et al. Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *European Journal of Medical Research*, 1997, 21:37–43.

68. Hadjiloizou SM, Bourgeois BD. (2005), Generalized seizures In: Bernard L. Maria's Current management in child neurology, third edi., BC Decker Inc, pp.105-116.
69. Hahn-Deinstrop E, Koch A, Muller M. Guidelines for the assessment of the traditional herbal medicine olibanum by application of HPTLC and DESAGA ProVi- Doc video documentation. *Journal of Planar Chromatography*, 1998, 11:404–410.
70. Hairfield EM, Hairfield HH Jr. McNair HM. GC, GC/MS, and TLC of -boswellic acid and O-acetyl- $\alpha$ -boswellic acid from *B. serrata*, *B. carteii* and *B. papyrifera*. *Journal of Chromatographic Science*, 1989, 27:127–133.
71. Hamm S et al. A chemical investigation by headspace SPME and GC-MS of volatile and semi-volatile terpenes in various olibanum samples. *Phytochemistry* 2005, 66:1499–1514.
72. Herrera-Ruiz M, Gutierrez CJ, Jimenez-Ferrer JE, Tortoriello J, Miron G, Leon I. (2007), Central nervous system depressant activity of an ethyl acetate extract from *Ipomoea stans* roots, *Journal of Ethnopharmacology*, 112, 243–247.
73. Hirokazu, O. (2004), Myoclonic epilepsies of infancy and childhood, myoclonus and myoclonic seizures. *Neurology Asia*, 9, 25–26.
74. Horhammer L, eds. Hagers Handbuch der pharmazeutischen Praxis, 4th ed. Berlin, Springer Verlag, 1975 [in German].
75. Hosseinzadeh H, Karimi G, Rakhshanizadeh M. (2005), Anticonvulsant effect of *Hypericum perforatum*: role of nitric oxide, *Journal of Ethnopharmacology*, 98, 207–208.
76. Hosseinzadeh H, Khosravan V. (2002), Anticonvulsant effect of *Crocus sativus* L. stigmas aqueous and ethanolic extracts in mice, *Archives of Iranian medicine*, 5, 44-47.
77. Huang MT, Badmaev V, Ding Y. (2000), Anti-tumor and anti-carcinogenic activities of triterpenoid, beta boswellic acid, *Biofactors*, 13, 225-230.
78. Ilhan A, Gurel A, Armutcu F, Kamisli S, Iraz M. (2005), Antiepileptogenic and antioxidant effects of *Nigella sativa* oil against pentylenetetrazol-induced kindling in mice, *Neuropharmacology*, 49, 456-464.
- In: Tomson T, Gram L, Sillanpää M, Johannessen S, editors. *Epilepsy and pregnancy*. Petersfield: Wrightson Biomedical; 1997. p. 71-80.

79. Irmak MK, Fadillioglu E, Gulec M, Erdogan H, Yagmurca M, Akyol. (2002). Effects of electromagnetic radiation from a cellular telephone on the oxidant and antioxidant levels in rabbits. *O Cell Biochem Funct. Dec*; 20(4):279-83.
80. J'agera AK, Mohotob SP, Heerdenc FR, Viljoen AM. (2005), Activity of a traditional South African epilepsy remedy in the GABA- benzodiazepine receptor assay, *Journal of Ethnopharmacology.*, 96, 603–606.
81. Johannessen SV. Pharmacokinetics of antiepileptic drugs in pregnant women.
82. Johnsen SD, TarbyTJ, Sidell AD. Carbamazepine induced seizures. *Neurology* 1984; 16:392-3.
83. Kamboj VP. (2000), Herbal medicine, General articles, *Current science*, 78 (1), 35- 51.
84. Kapil A, Moza N. Anticomplementary activity of boswellic acids, an inhibitor of C3-convertase of the classical complement pathway. *International Journal of Immunopharmacology*, 1992, 14:1139–1143.
85. Kapoor LD. Handbook of Ayurvedic medicinal plants. Boca Raton, CRC Press, 1990.
86. Kar A, Menon MK. Analgesic effect of the gum resin of *Boswellia serrata*. *Life Sciences*, 1969, 8:1023–1028.
87. Khandelwal KR. (2005), *Practical Pharmacognosy Techniques and Experiments*, Nirali Prakashan, India, pp.30-35.
88. Kimmatkar N et al. Efficacy and tolerability of *Boswellia serrata* extract in treatment of osteoarthritis of knee – a randomized double blind placebo controlled trial. *Phytomedicine*, 2003, 10:3–7.
89. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. (2003), Efficacy and tolerability of *Boswellia serrata* extract in treatment of osteoarthritis of knee – a randomized double blind placebo controlled trial, *Phytomedicine*, 10, 3-7.
90. King MA, Newton MR, Jackson GD, Fitt GJ, Mitchell LA, Silvapulle MJ, et al. Epileptology of the first seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. *Lancet* 1998; 352:1007-11.
91. Kirtikar KR, Basu BD. (1981), *Indian medicinal plants*. second ed., Lalit Mohan Basu: 49 Leader Road, Allahabad, India, 1, 521-522.



- 
92. Knaus U, Wagner H. (1996), Effects of boswellic acid of *Boswellia serrata* and other triterpenic acids on the complement system, *Phytomedicine*, 3, 77-81.
93. Koepp MJ, Woermann FG. (2005), Imaging structure and function in refractory focal epilepsy. *Lancet Neurology*, 4, 42 – 53.
94. Kokate CK, Purohit AP, Gokhale SB. (2006), Pharmacognosy, Nirali Prakashan, Pune, 36th Edition, 593-597.
95. Kokate CK. (1994), Handbook of Practical Pharmacognosy, fourth ed., Vallabh Prakashan, India, pp.58-61.
96. Krieglstein CF et al. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from *Boswellia serrata* resin, attenuates experimental ileitis. *International Journal of Colorectal Diseases*, 2001, 16:88–95.
97. Krieglstein CF, Anthoni C, Rijcken EJ, et al. (2001), Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from *Boswellia serrata* resin, attenuates experimental ileitis, *International Journal of Colorectal Disease*, 16, 88-95.
98. Kulkarni RR, Patki PS, Jog VP, et al. (1991), Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study, *Journal of Ethnopharmacology*, 33, 91-95.
99. Lambert MV, Robertson MM. (1999), Depression in epilepsy: etiology, phenomenology, and treatment, *Epilepsia*, 40 (10), S21 – S47.
100. Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. *Epilepsia* 1991; 32:257-66.
101. Li BY, Hu Y, Liang YZ, Xice PS. (2006), Ozaki Y, Modified secured principal component regression for detection of unexpeted chromatographic features in herbal fingerprints, *The Analyst*, 131, 538-546.
102. Linda Moretti Ojemann, Wendel L. Nelson, Donella S. Shin, Ann Ojemann Rowe, Robert A. Buchanan. (2006), Tian ma, an ancient Chinese herb, offers new options for the treatment of epilepsy and other conditions, *Epilepsy & Behavior*, 8, 376–383

103. Litchfield ST, Wilcoxon F. (1949), A simplified method of evaluating dose-effect experiments, *Journal of Pharmacology and Experimental Therapeutics*, 96, 99-105.
104. Loscher W, Honack D, Fassbender CP, Nolting B. (1991), The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs III, Pentylentetrazole seizure models. *Epilepsy Research*, 8, 171-189.
105. MacCabe RT, Wasterlaine CG, Kucharczyk N, Sofia RD, Vogel JR. (1993), Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors, *Journal of Pharmacology and Experimental Therapeutics*, 264, 1248-1252.
106. Mandal CS, Maity KT. (2000). Anti-inflammatory evaluation of *F. racemosa* linn. Leaf extract, *J. Ethnopharm.*, 72(1-2), 87-92.
107. Manilal A, Sujith S, Kiran GS, Selvin J and Shakir C. (2009). Biopotentials of Mangroves Collected from the Southwest Coast of India. *Global Journal of Biotechnology & Biochemistry*, 4 (1): 59-65.
108. Manjuan L, Seidel V, Katerere DR and Gray AI. (2007). Colorimetric broth microdilution method for the antifungal screening of plant extracts against yeasts, *Methods*, 42(4), 325-329.
109. Mao L, Sidransky D. (1994). Cancer screening based on genetic alterations in human tumors. *Cancer Res*, 54: 1939s-1940s.
110. Marshall NJ, Goodwin CJ, Holt SJ. (1995). "A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function". *Growth Regul.*; 5(2): 69-84.
111. Marson CA, Zivin LS. Factors related to the occurrence of typical paroxysmal abnormalities in the EEG records of epileptic patients. *Epilepsia* 1970 11 361-81.
112. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE. (1987). Clinical drug development: an analysis of phase II trials, 1970-1985. *Cancer Treat Rep.*; 71(1): 71-80.
113. Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, Ward RK, Lansdorp PM. (1998). Short telomeres on human chromosome 17p. *Nat Genet*, 18: 76-80.

114. Matesic L, Locke JM, Bremner JB, Pyne SG, Skropeta D, Ranson M, Vine KL. (2008). N-Phenethyl and N-naphthylmethyl isatins and analogues as *in vitro* cytotoxic agents. *Bioorganic & Medicinal Chemistry*, 16(6): 3118-3124.
115. McDonald RL, Kelly KM. (1995), Antiepileptic drugs mechanisms of action, *Epilepsia*, 36, S2-S12.
116. McNamara JO. (1996), Drugs effective in the therapy of epilepsies, In: Goodman and Gilman's "The Pharmacological Basis of Therapeutics", eleventh Ed., New York, pp. 501-525.
117. Meegan MJ, Carr M, Knox AJS, Zisterer DM, Lloyd DG. (2008).  $\beta$ -Lactam type molecular scaffolds for anti-proliferative activity: Synthesis and cytotoxic effects in breast cancer cells. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 23(5): 668-685.
118. Menon MK, Kar A. Analgesic and psychopharmacological effects of the gum resin of *Boswellia serrata*. *Planta Medica*, 1971, 19:333-341.
119. Merchant JR, Bakshi VM, Engineer AB. (1979).  $\beta$ -sitosterol, lupeol acetate and a compound, probably 13 $\alpha$ , 14 $\beta$ , 17 $\beta$  (H), 20 $\alpha$  (H)-lanosta-8, 22-diene-3 $\beta$ -ol have been isolated from the fruits of *F. glomerata*. *Ind. J. Chem.*, 17B, 87-88.
120. Merlo LM, Pepper JW, Reid BJ, Maley CC. (2006). "Cancer as an evolutionary and ecological process". *Nat. Rev. Cancer*; 6(12): 924-935.
121. Miles DH, Kokpol U, Chittawong V, Tip-Pyang S, Tunsuwan K & Nguyen C. (1998). Mangrove forests-The importance of conservation as a bioresource for ecosystem diversity and utilization as a source of chemical constituents with potential medicinal and agricultural value. *IUPAC*, 70 (11), 1-9.
122. Minna JD, Schiller JH. (2008). *Harrison's Principles of Internal Medicine* (17<sup>th</sup> ed.). McGraw-Hill. pp. 551-562.
123. Mohammad Sayyah, Ali Mandgary, Mohammad Kamalinejad. (2002), Evaluation of the anticonvulsant activity of the seed acetone extract of *Ferula gummosa* Boiss., against seizures induced by pentylenetetrazole and electroconvulsive shock in mice, *Journal of Ethnopharmacology*, 82, 105-109.
124. Mohapatra P, Shirwaikara A, Aswatharam H. (2008), Standardization of a Polyherbal Formulation, *Pharmacognosy Magazine*, 4(13), 65-69.
125. Mohsin Raza, Farzana Shaheen, M.I. Choudhary, Sompong Sombati, Azhar Rafiq, Amin Suria, Atta-ur- Rahman, R.J. DeLorenzo. (2001), Anticonvulsant

- activities of ethanolic extract and aqueous fraction isolated from *Delphinium denudatum*, *Journal of Ethnopharmacology*, 78, 73–78.
126. Momparler RL, Karon M, Siegel SE, Avila F. (1976). "Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells". *Cancer Res.*; 36(8): 2891–2895.
127. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, *et al.*, (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst*, 83(11): 757-766.
128. Morais LCSL, Barbosa-Filho JM, Almeida RN. (1998), Central depressant effects of reticuline extracted from *Ocotea duckei* in rats and mice, *Journal of Ethnopharmacology*, 62, 57–61.
129. Mori T, Matsumura M, Yamada K, Irie S, Oshimi K, Suda K, Oguri T, and Ichinoe M. (1998). Systemic aspergillosis caused by an aflatoxin-producing strain of *Aspergillus flavus*. *Med. Mycol.*, 36, 107-112.
130. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods*, 65: 55–63.
131. Mukherjee PK. (2005), Quality Control Herbal Drugs an Approach to Evaluation of Botanicals, 1st Edition Reprint, Business Horizons Pharmaceutical Publishers, New Delhi, 632.
132. Mukherjee PK, Saha. (1998). Screening of anti-diarrhoeal profile of some plant extract including *F. racemosa* of a specific region of west Bengal, *J. Ethnopharm.*, 60(1), 85-89.
133. Multani AS, Narayan S, Jaiswal AS, Zhao Y-J, Barkley RA, Furlong CL, Pathak S. (2002). Telomere dynamics, aging, and cancer: study of human syndromes characteristic of premature aging. *J Anti-Aging Med*, 5: 271–281.
134. Münger K, Hayakawa H, Nguyen CL, Melquiot NV, Duensing A, Duensing S, Bignold LP. (2006). Viral carcinogenesis and genomic instability. *Cancer: Cell Structures, Carcinogens and Genomic Instability*, Birkhäuser Verlag/Switzerland, 179-200.
135. Murbach Freire CM, Marques MM, Costa M. (2006), Effects of seasonal variation on the central nervous system activity of *Ocimum gratissimum* L. essential oil, *Journal of Ethnopharmacology.*, 105, 161–166.

136. Nachlas MM, Margulies SI, Goldberg JD, Seligman AM, (1960). The determination of lactic dehydrogenase with a tetrazolium salt. *Anal. Biochem.*, 317: 26.
137. Nadkarni KM. Indian materia medica. Bombay, Popular Prakashan, 1954.
138. Nag D. (2000), Gender and epilepsy – A clinician’s experience, *Neurol Ind*, 48, 99-104.
139. Nakayama GR, Caton MC, Nova MP, Parandoosh Z. (1997). Assessment of the Alamar Blue assay for cellular growth and viability in vitro. *Journal of Immunological Methods*, 204(2): 205-208.
140. Nardone RM, Rothblat GH, and Cristofalo J. (1977). *Toxicity testing in vitro., Growth, Nutrition and Metabolism of Cell in Culture*, volume III, Academic Press, New York, San Francisco, London, 471-495.
141. Nau H, Rating D, Koch S, Hauser I, Helge H. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. *J Pharmacol Exp Ther* 1981;219:768-77.
142. Negoescu A, Guillermet C, Lorimier P, Brambilla E, Labat-Moleur F. (1998). *Biomed. Pharmacother.*; 52(6): 252-258.
143. Ngo Bum E, Schmutz M, Meyer C, Rakotonirina A, Bopelet M, Portet C, Jeker A, Rakotonirina SV, Olpe HR, Herrling P. (2001), Anticonvulsant properties of the methanolic extract of *Cyperus articulatus* (Cyperaceae). *Journal of Ethnopharmacology*, 76, 145–150.
144. Nguелеfack TB, Nanab P, Atsamoa AD, Dimob T, Watcho P, Dongmoc AB, Tapondjou LA, Njamenb D, Wansi SL, Kamanyi A. (2006), Analgesic and anticonvulsant effects of extracts from the leaves of *Kalanchoe crenata* (Andrews) Haworth (Crassulaceae), *Journal of Ethnopharmacology*, 106, 70–75.
145. Nisar M, Khana I, Simjee SU, Gilani AH, Obaidullah Perveen H. (2008), Anticonvulsant, analgesic and antipyretic activities of *Taxus wallichiana* Zucc., *Journal of Ethnopharmacology*, 116, 490–494.
146. Nogueira E, Vassilieff VS. (2000), Hypnotic, anticonvulsant and muscle relaxant effects of *Rubus brasiliensis* Involvement of GABAA-system, *Journal of Ethnopharmacology*, 70, 275 - 280.
147. Norihiro B, Toshihiro A, Ken Y, Harukuni T, Keiichi T, Yuji N, Reiko N, Yumiko K, Takashi S. (2006), Anti-inflammatory activities of the triterpene acids

- from the resin of *Boswellia carteri*, *Journal of Ethnopharmacology*, 107, 249–253.
148. Ohman I, Tomson T, Vitols S. Lamotrigine levels in plasma and breast milk in nursing women and their infants [abstract]. *Epilepsia* 1998; 39(Suppl 2):21.
149. Ojewole AOJ. (2008b), Anticonvulsant property of *Sutherlandia frutescens* R. BR. (variety *Incana* E. MEY.) [Fabaceae] shoot aqueous extract, *Brain Research Bulletin.*, 75, 126–132.
150. Ojewole JAO. (2008a), Anticonvulsant effect of *Rhus chirindensis* (Baker F.) (Anacardiaceae) stem-bark aqueous extract in mice, *Journal of Ethnopharmacology*, 117, 130–135.
- on lysosomal stability in adjuvant induced arthritis. *Italian Journal of Biochemistry*, 1987, 36:205–217.
151. Paarakh PM. (2009). *Ficus racemosa* Linn.—An overview. *Natural Product Radiance*, 8(1), 84-90.
152. Patel PM, Patel KN, Patel NM, Goyal RK. (2006), Development of HPTLC method for estimation of charantin in herbal formulations, *Pharmacognosy Magazine*, 2(8), 224-226.
153. Pathak S. (2003). Cancer biology and genetic heterogeneity. *Proc Indian Natl Sci Acad*, B69: 11–22.
154. Pattison DI, Davies MJ, Bignold LP. (2006). Actions of ultraviolet light on cellular structures. *Cancer: Cell Structures, Carcinogens and Genomic Instability*, Birkhäuser Verlag/Switzerland, 131-158.
155. Paull KD. *et. al.*, (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and compare algorithm. *J. Natl. Cancer Inst.*; 81: 1088-1092.
156. Pellock JM, Duchowny M. (2005), Partial seizures In: Bernard L. Maria's *Current management in child neurology*, third edi., BC Decker Inc, pp.99-104.
157. Peter KV, Skaria BP. (2007), *Aromatic Plants (Horticulture Science Series I)*, New India Publishing Agency, New Delhi, India, pp.118-122.
158. Phillip Kruger, Rambod Daneshfar, Gunter P. Eckert, Jochen Klein, Dietrich A. Volmer, Ute Bahr, Walter E. Muller, Michael Karas, Manfred Schubert-Zsilavecz, and Mona Abdel-Tawab. (2008), Metabolism of Boswellic Acids in Vitro and in Vivo, *Drug Metabolism and Disposition*, 36, 1135-1142.

159. Phillipson JD. (2001), Phytochemistry and medicinal plants, *Phytochemistry*, 56, 237-243.
160. Poeckel D and Werz O. (2006), Boswellic acids: biological actions and molecular targets. *Curr Med Chem*, 13, 3359–3369.
161. Poonam Nina Banerjee, David Filippi, W. Allen Hauser. (2009), The descriptive epidemiology of epilepsy - A review, *Epilepsy Research*, 85, 31 – 45.
162. Porter RJ, Meldrum BS. (2001), Antiseizure Drugs in Basic and Clinical Pharmacology, McGraw Hill, New York, pp. 395-417.
163. Pourgholami MH, Majzoob S, Javadi M, Kamalinejad M, Fanaee GHR, Sayyah M. (1999), The fruit essential oil of *Pimpinella anisum* exerts anticonvulsant effects in mice, *Journal of Ethnopharmacology*, 66, 211–215.
164. Prajapati ND, Purohit SS, Sharma AK, Kumar T. (2006). A handbook of Medicinal Plants, a complete source book, In. Chap.2, History of Medicinal Plants: A World scenario; Agrobios (India); 02-10.
165. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission of Classification and Terminology of the International League against Epilepsy. *Epilepsia* 1981; 22:489-501.
166. Quintans LJ, Souza TT, Leite BS, Lessa NMN, Bonjardim LR, Santos MRV, Alves PB, Blank AF, Antonioli AR. (2008), Phytochemical screening and anticonvulsant activity of *Cymbopogon winterianus* Jowitt (Poaceae) leaf essential oil in rodents, *Phytomedicine*, 15, 619–624.
167. Rang HP, Dale MM, Ritter JM, Moore PK. (2003), Pharmacology, fifth edi., Churchill Livingstone, pp. 550-561.
168. Rao VS, Rao A, Karanth KS. (2005), Anticonvulsant and neurotoxicity profile of *Nardostachys jatamansi* in rats, *J. Ethnopharmacol.*, 102, 351-356.
169. Raper KB, DI Fennell. (1965). *The genus Aspergillus*. Williams & Wilkins, Baltimore.
170. Rauca, C., Zerbe, R., Jantze, H. (1999), Formation of free hydroxyl radicals after pentylenetetrazol- induced seizure and kindling, *Brain Research*, 847, 347-351.
171. Raza M, Shaheen F, Choudhary MI, Sambati S, Rafiq A, Suria A, Atta-ur-Rahman., DeLorenzo RJ. (2001), Anticonvulsant activities of ethanolic extract



- and aqueous fraction isolated from *Delphinium denudatum*, *Journal of Ethnopharmacology*, 78 (1), 73 - 78.
172. Reddy GK, Dhar SC. Effect of a new nonsteroidal anti-inflammatory agent
173. Reising K, Meins J, Bastian B, Eckert G, Mueller WE, Schubert-Zsilavec M, Abdel Tawab M. (2005), Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry, *Analytical Chemistry*, **77**, 6640–6645.
174. Renan MJ. (1993). How many mutations are required for tumorigenesis? Implications from human cancer data. *Mol Carcinog*, 7: 139–146.
175. Reutens DC, Berkovic SF. Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct. *Neurology* 1995; 45:1469-76.
176. Rho JM, Sankar R. (1999), The pharmacological basis of antiepileptic drug action, *Epilepsia*, 40, 1471–1483.
177. Ribeiro RA & Leite JR. (2003), Nantenine alkaloid presents anticonvulsant effect on two classical animal models, *Phytomedicine*, 10 (6-7), 563-568.
178. Richard MD, Warnock DW. (1997). *Fungal infection: Diagnosis and Management*, Blackwell publishing.
179. Riippi M, Antikainen O, Niskanen T, Yliruusi J (1998). The effect of compression force on surface structure, crushing strength, friability and disintegration time of erythromycin acistrate tablets. *Euro. J. Pharmac. Biopharmaceutics*, 46(3): 339-345.
180. Riss TL, Moravec RA. (2004). "Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays". *Assay Drug Dev. Technol.*; 2(1): 51–62.
181. Roberts and Spoon, *Handbook of Experimental Pharmacology*, 1990, 95, 419-458.
182. Rogawski MA, Porter RJ. (1995), Antiepileptic drugs and pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds, *Pharmacol Rev*, 42, 223 - 286.
183. Rohrs BR, Amidon GE, Meury RH, Secreast PJ, King HM, Skoug CJ (2006). Particle size limits to meet USP content uniformity criteria for tablets and capsules. *J. Pharmac. Sci.*, 95(5):1049-1059.



184. Rolland A, Fleurentin J, Lanhers MC, Younos C, Misslin R, Mortier F, Pelt JM. (1991), Behavioural effects of the American traditional plant *Eschscholzia californica*: sedative and anxiolytic properties, *Planta Medica*, 57, 212–216.
185. Rong LI, Jing-liang Z, Xiao-lu J, Hua-shi G. (2010). The Antifungal and Antitumor Activities of the Isolated Mangrove Forest Actinomycetes. *Journal of Food Science and Biotechnology*, 01.
186. Royal College of Physicians of Edinburgh. Consensus conference on better care for children and adults with epilepsy. Final consensus statement. Edinburgh: The College; 2002. [Cited 4 Apr 2003]. Available from url: [http://www.rcpe.ac.uk/esd/consensus/better\\_care\\_02.html](http://www.rcpe.ac.uk/esd/consensus/better_care_02.html)
187. Ruddon RW. (1995). *Cancer Biology, 3rd ed.* Oxford University Press, New York.
188. Rudiger K. (2002), Voltage- gated sodium channel in epilepsy, *Epilepsia*, 43, 1278 -1296.
189. Safayhi H, Boden SE, Schweizer S, Ammon HPT. (2000), Concentration - dependent potentiating and inhibitory effects of boswellia extracts on lipoxygenase product formation in stimulated PMNL. *Planta Medica.*, 66, 110 - 113.
190. Safayhi H, Rall B, Sailer ER, Ammon HPT. (1997), Inhibition by boswellic acids of human leukocyte elastase. *Journal of Pharmacology and Experimental Therapeutics.*, 281, 460-463.
191. Safayhi H, Sailer ER, Ammon HPT. (1992), Acetyl-11-keto-beta-boswellic acid: A non-competitive inhibitor of 5-lipoxygenase, *Journal of Pharmacology and Experimental Therapeutics*, 261, 1143 -1146.
192. Saha JC, Savini EC, Kasinathan S. Ecobolic properties of Indian Medicinal Plants. Part 1. *Indian Journal of Medical Research*, 1961, 49:130–151.
193. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HPT, Safayhi H. (1996), Acetyl-11-keto-b-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity, *Br J Pharmacol*, 117, 615–618.
194. Salinsky M, Kanter R, Dasheiff RM. Effectiveness of multiple EEGs in supporting the diagnosis of epilepsy: an operational curve. *Epilepsia* 1987; 28:331-4.

195. Sandberg AA. (1990). *The Chromosomes in Human Cancer and Leukemia*. Elsevier, New York.
196. Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. *Lancet* 1990; 336:1267-71.
197. Sander JW, Shorvon SD. Epidemiology of the epilepsies. *J Neurol Neurosurg Psychiatry*; 61: 433-43.
198. Sander O, Herborn G, Rau R. (1998), Is H15 (resin extract of *Boswellia serrata*, “incense”) a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study, *Zeitschrift für Rheumatologie*, 57, 11-16.
199. Sander O, Herborn G, Rau R. Is H15 (resin extract of *Boswellia serrata* “incense”) a useful supplement to establish drug therapy of chronic polyarthritis? Results of a double-blind pilot study. *Zeitschrift für Rheumatologie*, 1998, 57:11–16.
200. Sankari M, Chitra V, Silambujanaki P, Raju D. (2010), Anticonvulsant Activity of Ethanolic Extract of *Aegle marmelos* (Leaves) in Mice, *International Journal of PharmTech Research*, Vol.2, No.1, pp 640 - 643.
201. Sasco AJ, Secretan MB, Straif K. (2004). "Tobacco smoking and cancer: a brief review of recent epidemiological evidence". *Lung cancer (Amsterdam, Netherlands)*, 45 Suppl (2): S3–9.
202. Sausville EA and Feigal E. *et al.* (1999). Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA, *Annals of Oncology*; 10: 1287-1291.
203. Sayyah M, Mandgary A, Kamalinejad M. (2002), Evaluation of the anticonvulsant activity of the seed acetone extracts of *Ferula gummosa* Boiss., against seizures induced by pentylenetetrazole and electroconvulsive shock in mice, *Journal of Ethnopharmacology*, 82, 105-109.
204. Sayyah M, Moaied S, Kamalinejad M. (2005), Anticonvulsant activity of *Heracleum persicum* seed. *Journal of Ethnopharmacology*, 98, 209–211.
205. Sayyah M, Nadjafnia L, Kamalinejad M. (2004), Anticonvulsant activity and chemical composition of *Artemisia dracunculus* L. essential oil, *Journal of Ethnopharmacology*, 94, 283–287.

206. Schachter SC. (2009), Botanicals and Herbs: A Traditional Approach to Treating Epilepsy, *Neurotherapeutics*, Vol. 6, No. 2.
207. Schachtrup C, Lu P, Jones LL, *et al.* (2007). "Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor". *Proc. Natl. Acad. Sci. U.S.A.*, 104(28): 11814–11819.
208. Scheepers B, Clough P, Pickles C. The misdiagnosis of epilepsy: findings of a population study. *Seizure* 1998; 7:403-6.
209. Schmidt D, Gram L. (1995), Monotherapy versus polytherapy in epilepsy, *CNS Drug*, 3, 94–208.
210. Schurmann da Silva AF, Paulo de Andrade J, Bevilaqua LRM, Maria de Souza M, Izquierdo I, Henriques AT, Zuanazzi JAS. (2006), Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from *Hippeastrum vittatum*, *Pharmacology Biochemistry and Behavior*, 85, 148–154.
211. Schweizer S *et al.* Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues. *Journal of Natural Products*, 2000, 63:1058–1061.
212. Semah F, Picot MC, Adam C, *et al.* (1998), Is the underlying cause of epilepsy a major prognostic factor for recurrence? *Neurology*, 51, 1256 – 62.
213. Sen AB, Chowdhury AR. (1971). A new tetracyclic tentatively named gluanol acetate,  $\beta$ -amyrin and  $\beta$ -sitosterol have been isolated from the leaves of *Ficus glomerata* Roxb. *J. Ind. chem. Soc.*, 48(12), 1165-1169.
214. Shaker KH, Elgamal MHA, Seifert K. (2001). Iridoids from *Avicennia Marina*. *Zeitschrift Fuer Naturforschung C J. Biosci.*, 56, 965-968.
215. Shanafelt TD, Lin T, Geyer SM, *et al.*, (2007). "Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia". *Cancer*, 109(11): 2291–2298.
216. Shao Y, Ho CT, Chin CK. (1998), Inhibitory activity of boswellic acids from *Boswellia serrata* against human leukemia HL-60 cells in culture, *Planta Medica*, 64, 328-331.
217. Sharaf M, El-Ansari M, Saleh NAM. (2000). New flavonoids from *Avicennia marina*. *Fitoterapia*, 71, 274-277.

218. Sharma ML, Bani S, Singh GB. (1999), Anti-arthritis activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis, *Int J Immunopharmacol*, 11, 647-652.
219. Sharma ML, Khajuria A, Kaul A. (1998), Effects of salai guggal ex-*Boswellia serrata* on cellular and humoral immune responses and leukocyte migration *Agents Actions*, 24, 161-164.
220. Sharma RC, Zaman A, Kidwai AR. (1963).  $\beta$ -sitosterol and lupeol have been isolated from the petroleum ether extract of the root bark of *F. racemosa* Linn. *Ind. J. Chem.*, 1, 365-366.
221. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R. (2004), Pharmacokinetic study of 11-keto b-Boswellic acid, *Phytomedicine*, 11, 1255-1260.
222. Sharma HL, Sharma KK. (2008). Principal of pharmacology. In chap. 41, Antiepileptic drugs, Paras Medical Publisher, First Edition, 529-534.
223. Shinnar S, Berg AT. (1996), Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? *Epilepsia*, 37, 701 - 708.
224. Shoemaker RH. *et al.* (1988). Development of human tumor cell line panels for use in disease-oriented drug screening. *Prog. Clin. Biol. Res.*; 276: 265-286.
225. Shrikumar S, Ravi TK. (2007), Approches towards Development and Promotion of Herbal Drugs, *Pharmacognosy Reviews*, 1(1), 180-184.
226. Singh D, Goel RK. (2009), Anticonvulsant effect of *Ficus religiosa*: Role of serotonergic pathways, *Journal of Ethnopharmacology*, 123, 330-334.
227. Singh GB, Atal CK. (1986), Pharmacology of an extract of salai guggal ex-*Boswellia serrata*, a new nonsteroidal anti-inflammatory agent. *Agents Actions*, 18, 407-412.
228. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-*Boswellia serrata*, a new nonsteroidal anti-inflammatory agent. *Agents and Actions*, 1986, 18:407-412.
229. Singh GB, Bani S, Singh S. Toxicity and safety evaluation of Boswellic acids. *Phytomedicine*, 1996, 3:87-90.

230. Singh GB. (2008), Pharmacological profile of boswellic acids obtained from *Boswellia serrata* as a new type of non-steroidal anti-inflammatory drug, *Phytomedicine*, 15, 541–546.
231. Singh S, Khajuria A, Taneja SC, Khajuria RK, Singha J, Qazia GN. (2008), Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders, *Phytomedicine*, 15, 400–407.
232. Singh S, Khajuria A, Taneja SC, Khajuria RK, Singha J, Qazia GN. (2007), Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats, *Bioorganic and Medicinal Chemistry Letter*, 17, 3706–3711.
233. Sinha KK. (2002), Epilepsy, *Neuroscience*, 6, 195-203.
234. Sirisha N, Sreenivasulu M, Sangeeta K, Madhusudhana Chetty C. (2010). Antioxidant Properties of Ficus Species – A Review. *International Journal of PharmTech Research*, 2(4), 2174-2182.
235. Sirtori SG. (2000), Clinical Pharmacol., Mc Graw Hill Publications Press, United Kingdom.
236. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. *QJM* 1999; 92:15-23.
237. So ML. (1990). *Antifungal activities of mangrove plants*. International Conference on Plant Protection in the Tropics, Genting Highlands, Pahang (Malaysia), 20-23 Mar, MY9305418.
238. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ. (2003) Zonisamide: A new antiepileptic drug. *Polish Journal of Pharmacology*, 55, 683 - 689.
239. Sohn SH, Multani AS, Gugnani PK, Pathak S. (2002). Telomere erosion-induced mitotic catastrophe in continuously grown Chinese hamster Don cells. *Exptl Cell Res*, 279: 271–276.
240. Solanki, Ranjitsinh. *Herbal formulation*. US 2004/0009240 A1, Application No. US 10/257083, PCT Filed: WO PCT/IB02/02698.
241. Sonavane GS, Palekar RC, Kasture VS and Kasture SB. (2002), Anticonvulsant and Behavioural Actions of *Myristica fragrans* seeds, *Indian Journal of Pharmacology*, 34, 332-338.
242. Sowa M, Arthurs MJ, Estes JB, Morgan WF, Bignold LP. (2006). Effects of ionizing radiation on cellular structures, induced instability and carcinogenesis.

- Cancer: Cell Structures, Carcinogens and Genomic Instability*, Birkhäuser Verlag/Switzerland, 293-302.
243. Spooner CG, Berkovic SF, Mitchell LA, Wrennall JA, Harvey AS. (2006), New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. *Neurology*, 67, 2147 – 53.
244. Stephen Hsu, Fu-Xin Yu *et al.* (2003). A Mechanism-Based *In-vitro* Anticancer Drug Screening Approach for Phenolic Phytochemicals assay and Drug Development Technologies, *Drug Development Technologies*; 1(5).
245. Sterk V, Buchele B, and Simmet T. (2004), Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. *Planta Med*, 70, s1155–1160.
246. Steven CS. (2009), Botanicals and Herbs: A traditional approach to treating epilepsy. *Neurotherapeutics*, Vol. 6, No. 2, 415 – 420.
247. Stockley IH. (1998), Drug interactions, The Pharmaceutical Press., London., U.K.
248. Subashree M, Mala P, Umamaheswari M, Jayakumari M, Maheswari K. (2010). Screening of the antibacterial properties of *Avicennia marina* from pichavaram mangrove. *International Journal of Current Research*, 1, 16-19.
249. Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA. (1995), Felbamate block of the N-methyl-Daspartate receptor, *Journal of Pharmacology and Experimental Therapeutics*, 273, 878-886.
250. Suggitt, M. and Bibby MC. (2005). 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. *Clin. Cancer Res.*; 11: 971-81.
251. Sugimoto K, Yamada K, Egashira M, Yazaki Y, Hirai H, Kikuchi A and Oshimi K. (1998). “Temporal and Spatial Distribution of DNA Topoisomerase II Alters During Proliferation, Differentiation, and Apoptosis in HL-60 Cells”. *Blood*, 91(4): 1407-1417.
252. Sukhramani PS, Sukhramani PS, Tirthani SR, Desai SA, Suthar MP. (2011). Biological cytotoxicity evaluation of spiro[azetidine-2, 3'-indole]-2', 4(1'H)-dione derivatives for anti-lung and anti-breast cancer activity, *Der Pharmacia Lettre*, 3(5), 236-243.

253. Sukhramani PS, Suthar MP. (2010). VEGF Inhibitors for Cancer Therapy. *International Journal of Pharmaceutical Sciences and Drug Research*; 2(1): 01-11.
254. Sun Y, Ouyang J, Deng ZW, Li QS, Lin WH. (2008). Structure elucidation of five new iridoid glucosides from the leaves of *Avicennia marina*. *Magn. Reson. Chem.*, 46, 638-642.
255. Sun, C, Himmelspach MW (2006). Reduced tableability of roller compacted granules as a result of granule size enlargement. *J. Pharmac. Sci.*, 95(1): 200-206.
256. Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C. (1990). Intracellular concentrations of anti cancer drugs in leukemic cells *in vitro* vs *in vivo*. *Cancer Chemother. Pharmacol.*; 25(4): 252-256.
257. Sutaria RN. (1969). *A text book of systematic botany*, 5<sup>th</sup> ed., Khardayata book depot.
258. Suthar MP, Patel PN, Shah TG, Patel RK. (2010). *In-vitro* Screening of *Nigella sativa* Seeds for Antifungal Activity, *International Journal of Pharmaceutical and Applied Sciences*, 1 (2), 84-91.
259. Sutton D, Gillan FT, Susic M. (1985). Naphthofuranone phytoalexins from the grey mangrove, *Avicennia marina*. *Phytochemistry*, 24, 2877-2879.
260. Sutton DA, Fothergill AW, Rinaldi MG (ed.). (1998). *Guide to Clinically Significant Fungi*, 1<sup>st</sup> ed. Williams & Wilkins, Baltimore.
261. Swinyard EA. (1969), Laboratory evaluation of antiepileptic drugs. Review of laboratory methods, *Epilepsia*, 10, 107-119.
262. Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet T. (2000), Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II alpha, *Molecular Pharmacology.*, 58, 71-81.
263. Syrovets T, Buchele B, Krauss C, Laumonnier Y, Simmet T. (2005), Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases, *Journal of Immunological Methods*, 174, 498-506.
264. Tajbakhsh S, Mahmoodpour M and Haghghi MA. (2005). Antibacterial activity of *Avicennia marina* leaves extract on *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. *Iranian south medical of Journals*, 8(1): 1-7.



- 
265. Takeuchi A, Takeuchi N. (1969), A study of the action of picrotoxin on the inhibitory neuromuscular junction in crayfish. *J Physiol*, 205, 377–391.
266. Tallis RC. (2002), Epilepsy and seizures in geriatric practice. In: Duncan JS, Sisodiya SM, Smalls JE, editors, Epilepsy from science to patient. Bristol: Burleigh ress Ltd. p. 369–73.
267. Tamizhmani T, Ponnusankar S, Nancy J, Suresh B. (2003), Toxicity of using Herbs, *The Indian Pharmacist*, 14 (2), 13.
268. Tariq M, Dawar S, Mehdi FS and Zaki MJ. (2006). Use of *Avicennia marina* in the control of root infecting fungi on okra and mash bean. *Pak. J. Bot.*, 38(3): 811-815.
269. Tassinari CA, Bureau M, Thomas P. (1992), Epilepsy with myoclonic absences. In Roger J, Bureau M, Dravet C, Dreifuss FE, Wolf P, eds. *Epileptic syndromes in infancy, childhood, and adolescence*. 2nd ed. London; John Libbey; 151-160.
270. *The Ayurvedic pharmacopoeia of India, Part I, Vol. IV*. New Delhi, Ministry of Health and Family Welfare, Department of Indian System of Medicine and Homeopathy, 1999.
271. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. *Epilepsia* 1994; 35:122-30.
272. Torta R, Keller R. (1999). Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. *Epilepsia*, 40 (10), S2–S20.
273. Trubestein G. (1999), Volatile constituents of natural *Boswellia serrata* oleo-gum-resin and commercial samples, *Biology and Medicine journal*, 28, 121–124.
274. US Pharmacopeia National Formulary USP 23/NF 18 (1995). United States Pharmacopeial Convention. Inc., Rockville, MD.
275. Vaidhya ADB. (1997), Status and scope of Indian medicinal plants acting on central nervous system, *Indian Journal of Pharmacology*, 29, 5340-5353.
276. Vasconcelos SMM, Lima NM, Sales GTM, Cunha GMA, Aguiar LMV, Silveira ER, Rodrigues ACP, Macedoa DS, Fonteles MF, Sousa FF, Viana GB. (2007), Anticonvulsant activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu*, *Journal of Ethnopharmacology*, 110, 271–274.



277. Vayalil PK (2002). Antioxidant and Antimutagenic Properties of Aqueous Extract of Date Fruit (*Phoenix dactylifera* L. Arecaceae). *J. Agri. Food Chem.*, 50(3):610-617.
278. Verghese J et al. A fresh look at the constituents of Indian Olibanum oil. *Flavor and Fragrance Journal*, 1987, 2:99–102.
279. Virtanen S, Antikainen O, Rääkkönen H, Yliruusi J (2010). Granule size distribution of tablets", *J. Pharmac. Sci.*, 99(4): 2061-2069.
280. Vyawahare NS, Khandelwal AR, Batra VR, Nikam AP. (2007), Herbal anticonvulsants, *Journal of herbal medicine and toxicology*, 1, 9 –14.
281. Wagner H. (1999), Search for new plant constituents with potential antiphlogistic and antiallergic activity, *Planta Medica*, 55, 235-241
282. Wambebe C. (1985), Influence of some agents that affect 5-hydroxy-tryptamine metabolism and receptors on nitrazepam-induced sleep in mice, *British Journal of Pharmacology*, 84, 185-191.
283. Wang W, Hu X, Zhao Z, Liu P, Hu Y, Zhou J, Zhou D, Wang Z, Guo D, Guo H. (2008), Antidepressant-like effects of liquiritin and isoliquiritin from *Glycyrrhiza uralensis* in the forced swimming test and tail suspension test in mice, *Prog Neuropsychopharmacol Biol Psychiatry*, 32, 1179–1184.
284. Warlow CP, Sandercock PAG, Hankey GJ, Van Gijn J, Dennis MS, Bamford J, et al. *Stroke: A practical guide to management*. 2nd ed. Malden (MA): Blackwell Science; 2000.
285. Weber CC, Reising K, Müller WE, Schubert-Zsilavecz M, Abdel Tawab M. (2006), Modulation of P-gp function by boswellic acids, *Planta Medica*, 72, 507–513.
286. Westerhuis JA, Coenegracht PMJ (1997). Multivariate modelling of the pharmaceutical two-step process of wet granulation and tableting with multiblock partial least squares. *J. Chemometrics*, 11(5): 379- 392.
287. Westmoreland BF, Benarroch EE, Dube JR, Regan TJ, Sandok BA. (1994), *Med Neurosci*. Mayo Foundation, Rochester, 307-312.
288. WHO guidelines on assessing quality of herbal medicines with reference to contaminants and residues. Geneva, World Health Organization, 2007.
289. Wichtl M. *Teedrogen und phytopharmaka*. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 2002 [in German].

290. Wickenden AD. (2002), Potassium channels as antiepileptic drug targets, *Neuropharmacology*, 3, 1055–1060.
291. Winking M, Sarikaya S, Rahmanian A, Jodicke A, and Boker DK. (2000), Boswellic acids inhibit glioma growth: a new treatment option, *Journal of Neurooncology*, 46, 97–103.
292. Yalkowsky SH, Bolton S (1990). Particle Size and Content Uniformity. *Pharmaceutical Research*, 7(9):962-966.
293. Yemitan OK, Adeyemi OO. (2005), CNS depressant activity of *Lecaniodiscus cupanioides*, *Fitoterapia*, 76, 412–418.
294. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. *Neurology* 1992; 42:12-6.
295. Zanolini P, Rivasi M, Zavatti M, Brusiani F, Baraldi M. (2005), New insight in the neuropharmacological activity of *Humulus lupulus* L, *Journal of Ethnopharmacology*, 102, 102–106.